February 27, 2019
Heron’s Civanti supplemental NDA accepted by FDA
Heron Therapeutics said Wednesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) injectable emulsion, for intravenous (IV) use.
